http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 Aug 2025 02:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372 http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences Inc.</span> ("<span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span>", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&amp;D progress.</p> <p>Financially, the company achieved record revenue, driven by the strong performance of its core product, <b>Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®</b>. The drug generated net sales of approximately <money>RMB 170 million</money>. <span value="ACORN:2446751191" idsrc="xmltag.org" >Keymed</span> strengthened its balance sheet with a successful placement raising <money>~HK$864 million</money>, providing ample funds for pipeline development and commercialization.</p> <p>The differentiated R&amp;D pipeline advanced significantly. Key highlights include:</p> <ul http://www.streetinsider.com/PRNewswire/Keymed+Biosciences+%2802162.HK%29+Reports+Strong+Interim+2025+Results+with+Accelerated+Commercialization+and+Robust+R%26amp%3BD+Momentum/25255972.html Wed, 27 Aug 2025 02:02:00 -0400 02162 2162 64Z A.00423054 A.09649487 A.24467511 A.35846118 O.00018297 O.00048429 O.00400076 O.00609993 O.05105669 O.50329372